A diverse, summer issue with articles on topics ranging from content marketing to the role of experience in a VUCA world. Also, the latest book for Medical Reps reviewed by Prof. Vivek Hattangadi

Eli Lilly’s $6.5 Billion Houston Bet: A Strategic Play in U.S. Manufacturing, Policy, and the Next Wave of Obesity Treatment

When Eli Lilly announced plans to build a $6.5...

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

Key Challenges Facing Indian Pharma

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience. The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.